Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

MannKind, United Therapeutics Ink $95 Million+ Deal

MannKind Corp. and United Therapeutics Corp. signed a worldwide exclusive license and collaboration deal to develop and commercialize a dry powder formulation of treprostinil being studied in clinical trials to treat pulmonary arterial hypertension.

Read More »

Emergent BioSolutions to buy Narcan maker Adapt Pharma

Emergent BioSolutions will buy privately held Adapt Pharma, beefing up its portfolio with Narcan, the only FDA-approved needle-free emergency opioid overdose treatment.

Read More »

Bayer teams up with Evotec, Haplogen

Collaboration partners Evotec AG and Haplogen GmbH announced that Haplogen will enter into a multi-year drug discovery and development deal with Bayer AG to focus on pulmonary diseases.

Read More »

Orchard raises $150 million to expand

Orchard Therapeutics raised a further $150 million to fund the biotech company’s work in gene therapy, building on earlier fundraisings worth more than $140 million.

Read More »

Galapagos, MorphoSys Ink Potential $1.1+ Billion Deal With Novartis

Galapagos and MorphoSys signed an exclusive development and commercialization deal with Novartis for a drug compound being developed for the treatment of inflammatory diseases.

Read More »

Justice Department Gives Go-Ahead To CVS, Aetna Deal

The U.S. Justice Department will not challenge the $69 million merger of CVS Health and health insurer Aetna.

Read More »

Kallyope, Novo Nordisk Team Up To Tackle Obesity

New York-based Kallyope and Danish company Novo Nordisk signed a research collaboration and option deal to discover novel therapeutics to treat obesity and diabetes.

Read More »

Roche pays $2.4 billion for rest of cancer expert Foundation Medicine

Roche is paying $2.4 billion to buy the rest of Foundation Medicine, raising the Swiss drugmaker’s bet on the U.S. genomic profiling group’s ability to personalize cancer care.

Read More »

Novartis Pays Regenxbio $100 Million for Gene Therapy Technology Under AveXis License Agreement

Rockville, Md.-based REGENXBIO snagged $100 million from Novartis under its license agreement with gene-therapy company AveXis, which the Swiss company acquired for $8.7 billion earlier in 2018.

Read More »

Biogen Options Stroke Drug from TMS

Biogen, headquartered in Cambridge, Massachusetts, signed an exclusive option deal with Tokyo-based TMS for TMS-007 and backup compounds.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom